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Neuroendocrine tumors (NETs) are found throughout the body and are important as they
give rise to distinct clinical syndromes. Glycosaminoglycans, in proteoglycan (PG) form or
as free chains, play vital roles in every step of tumor progression. Analyzing tumor samples
with different degrees of histological differentiation we determined the existence of impor-
tant alterations in chondroitin sulfate (CS) chains. Analysis of the transcription of the genes
responsible for the production of CS showed a decline in the expression of some genes
in poorly differentiated compared to well-differentiated tumors. Using anti-CS antibodies,
normal stroma was always negative whereas tumoral stroma always showed a positive
staining, more intense in the highest grade carcinomas, while tumor cells were negative.
Moreover, certain specific cell surface PGs experienced a drastic decrease in expression
depending on tumor differentiation. Syndecan 2 levels were very low or undetectable in
healthy tissues, increasing significantly in well-differentiated tumors, and decreasing in
poorly differentiated NETs, and its expression levels showed a positive correlation with
patient survival. Glypican 5 appeared overexpressed in high-grade tumors with epithelial
differentiation, and not in those that displayed a neuroendocrine phenotype. In contrast,
normal neuroendocrine cells were positive for glypican 1, displaying intense staining in
cytoplasm and membrane. Low-grade NETs had increased expression of this PG, but this
reduced as tumor grade increased, its expression correlating positively with patient sur-
vival. Whilst elevated glypican 1 expression has been documented in different tumors, the
downregulation in high-grade tumors observed in this work suggests that this proteogly-
can could be involved in cancer development in a more complex and context-dependent
manner than previously thought.
Keywords: neuroendocrine tumor, proteoglycan, glycosaminoglycan, syndecan 2, glypican 1, chondroitin sulfate,
glypican 5
INTRODUCTION
The neuroendocrine tumors (NETs) comprise a heterogeneous
group of neoplasms, which express typical characteristics of cells
of the neuroendocrine system, which in itself constitutes a dif-
fuse structure that includes several cell types, which arise in tissues
derived from the embryonic neural crest, specific zones of neuroec-
toderm and endoderm, and have many histological similarities to
neural cells, such as secretory granules, similar cellular antigens
and the fact they contain the potential markers chromogranin A,
synaptophysin, and neurone-specific enolase. They produce bioac-
tive substances such as peptide hormones and biogenic amines that
serve a transmitter function (1).
The incidence of NETs is two cases per 100,000 people, and
they account for 0.5% of all malignancies. NETs can arise in
many different parts of the body including the gastrointestinal
(GI) tract, lung, pancreas, thymus, adrenal glands, ovary, and thy-
roid. However, approximately two-thirds of NETs are found in
the GI tract, and approximately one-quarter occur in the lung,
thus the two locations account for about 90% of such tumors
(2). Although most NETs occur as sporadic tumors, in some cases
the risk of their development is significantly increased by several
genetic syndromes such as multiple endocrine neoplasia types 1
and 2, neurofibromatosis type 1, von Hippel–Lindau disease, and
tuberous sclerosis (3).
Some characteristics of NETs are specific to where they are
located. Nonetheless, in general and according to WHO guide-
lines, these neoplasms are divided into well-differentiated and
poorly differentiated. Well-differentiated NETs have a character-
istic organoid arrangement of the tumor cells, and in general are
either low or intermediate grade with mitotic activity and Ki67
proliferative index of under 20%. In contrast, poorly differenti-
ated NETs display a more sheetlike or diffuse architecture, higher
mitotic activity and are considered high-grade in all cases (4). The
highest malignancy grade tumors are further subclassified as either
large cell NETs, which show anaplastic neuroendocrine growth
with a more epithelial-like morphology and larger cellular size,
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or small cell anaplastic NETs, with smaller cell size, occasionally
neural-like pseudorosettes and which are more similar to primitive
neuroectodermal tumors (5).
Various studies have addressed the analysis of the differential
gene expression profile in NETs and have identified alterations
affecting a variable number of transcripts, ranging from around a
hundred to a thousand depending on the study design and experi-
mental analysis (6–9). Among the genes whose expression is altered
there are some putative oncogenes, growth-factor related genes,
transcription factors, apoptosis-related genes, and genes involved
in signal transduction, cell adhesion and migration, cell growth,
and cell death (6–9). Interestingly, although several of these genes
have functional relationships with proteoglycans (PGs), up to
now the studies performed have detected scarce changes in the
expression of genes encoding these molecules.
Proteoglycans are a diverse group of glycoconjugates composed
of different core proteins post-translationally modified with one
or more covalently attached glycosaminoglycan (GAG) chains.
GAGs are linear anionic polysaccharides made up of repeating
disaccharides containing acetylated amino sugar moieties and
acid, mainly uronic. Differences in the type of monosaccharide
in the repeating unit, as well as their sulfation, result in the
various types of GAGs. Heparan sulfate (HS) and chondroitin
sulfate (CS) are the two most widespread forms of sulfated GAGs,
being present in all cell types and tissues at the extracellular and
cellular levels. HS consists of repeating disaccharide units of N -
acetylglucosamine (GlcNAc) and hexuronic acid residues while
in CS GlcNAc is substituted by N -acetylgalactosamine (GalNAc)
(Figure 1).
Heparan sulfate and CS synthesis occurs mainly in the Golgi
apparatus and is initiated by the formation of a tetrasaccharide
linkage on a cognate serine residue of the PG core, synthesized
by stepwise addition of xylose, two galactose units, and a glu-
curonic acid (GlcA) residue. The addition of this residue is the
crucial factor in determining which GAG will be synthesized; while
the incorporation of GalNAc initiates CS elongation, addition of
GlcNAc results in HS formation (10). Subsequently, the HS and
CS chains are elongated by the addition of alternating GlcA and
GlcNAc or GlcA and GalNAc residues respectively. At various posi-
tions, the molecules are modified by a series of interdependent
enzymatic reactions that may include the epimerization of GlcA
to iduronate (IdoA), and different sulfations of both the uronic
acid and the amino sugar moieties (Figure 1) (11, 12). In HS,
chain modification results in clusters of highly sulfated regions
(10), while in CS it gives rise to the various different characteristic
chains, CS-A, CS-C, CS-D, CS-E, and CS-B, the latter also being
known as dermatan sulfate (DS) (12).
Chondroitin sulfate and HS chains are able to interact selec-
tively with many different types of ligands, including soluble
factors, membrane proteins and the extracellular matrix (ECM),
lipids, and even microorganisms. HSPGs and CSPGs are mainly
associated with the cell surface and the ECM and a variety of
both normal and pathological functions have been ascribed to
them, including cell adhesion and migration, organization of the
ECM, regulation of proliferation, differentiation and morpho-
genesis, cytoskeleton organization, tissue repair, inflammation,
vascularization, and cancer metastasis (12, 13).
FIGURE 1 | Chondroitin sulfate and HS biosynthesis. Biosynthesis
begins with the addition of a xylose to specific serine residues acceptor of
a PG core protein. Subsequently, the biosynthesis continues with the
stepwise addition of two galactose units, and a GlcA. HS chain extension
requires the subsequent transference of a GlcNAc residue, while the
addition of a GalNAc directs the pathway toward the biosynthesis of CS.
Sites of action of the enzymes involved in the initiation of the synthesis of
GAG chains and in the modification of the CS disaccharide unit are indicated.
Proteoglycans may play diverse roles in cancer and act as either
inhibitors or promoters of tumor progression depending on the
type and stage of the cancer. They have been found to be involved
in several aspects of tumor biology including cell proliferation,
adhesion and migration, inflammation, and angiogenesis (12–
15). The expression of PGs is markedly altered during malignant
transformation and tumor progression, affecting both the PG core
proteins and the GAG chains (15, 16). As a result of their ability to
interact with diverse molecules, PGs also regulate signaling in non-
neoplastic components of the tumor, and have important roles in
regulating the immune response to cancer (15, 17).
Unlike other neoplastic transformations, there is little informa-
tion concerning alterations of PGs in NETs. Some studies report
changes associated with malignant transformation, such as the
increased expression of lumican in carcinoid compared to neu-
roendocrine cell carcinomas, suggesting that this PG may play a
role in the slow growth of these tumors (18). The overexpression
of EXTL2 in patients with MEN1 syndrome (8) has also been evi-
denced, as well as alterations in the levels of versican, biglycan,
DSPG 3, perlecan, and CD44 in pancreatic endocrine tumors and
their liver metastasis (19).
In this paper, we investigate the expression of PGs in NETs of
different malignancy grade. By means of differential transcription
studies we identify genes whose expression is significantly altered
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between tumors of low and high-grade. Subsequently, we analyze
the alterations in the products of these genes, PGs or GAGs as
appropriate, using immunohistochemistry, as well as their correla-
tion with cell differentiation, grade and stage of tumor, and patient
survival. Given the large number of genes involved in the biosyn-
thesis of these complex molecules, we focus the analysis on two
specific families that have been shown to be strongly involved in
tumor transformation in other neoplastic processes: HSPG core
proteins and enzyme encoding CS chains. The aim of the work
was to detect genes whose expression may be related to tumor
aggressiveness and which might be able to predict the behavior of
NETs. These genes could, in the future, be useful in developing
new chemical biology approaches to retarding tumor progression
by modulating the deregulated biosynthetic pathways.
MATERIALS AND METHODS
MATERIALS
The following materials were purchased from the manufactur-
ers indicated: RNeasy Kit and RNase-Free DNase from Qiagen
(Hilden, Germany); High-Capacity cDNA Reverse Transcription
Kit and PowerSYBR Green PCR Master Mix from Applied Biosys-
tems (Foster City, CA, USA); GenElute PCR clean-up kit and 3,3′-
diaminobenzidine from Sigma-Aldrich (St. Louis, MO, USA); and
EnVision™ G|2 Doublestain System and EnVision FLEX Target
Retrieval Solution of High pH from Dako (Glostrup, Denmark).
All other chemicals were obtained from commercial sources and
were of analytical grade.
The following antibodies were used in this study: rabbit anti-
syndecan 2 (M-140) was from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA); rabbit anti-glypican 1 polyclonal anti-
body from Thermo Scientific (Thermo Fisher Scientific Inc.,
Waltham, MA, USA); rabbit anti-glypican 5 monoclonal antibody
from Novus Biologicals (Littleton, CO, USA); monoclonal anti-
CS clone CS-56, purchased from Sigma-Aldrich (St. Louis, MO,
USA); and anti-mouse (sc-2020) and anti-rabbit (sc-2004) sec-
ondary antibodies, from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
PATIENTS AND SAMPLES
Thirty-nine patients with gastroenteropancreatic (GEP) and pul-
monary neuroendocrine tumors (L-NETs) were recruited at the
Biobank of the Hospital Universitario Central of Asturias between
February 2000 and October 2009. Institutional review board
approval in relation to guidelines on ethical procedures, and
patient informed consent for research on the samples were sought
and given. The diagnosis of NETs was based on morphologi-
cal criteria according to the updated World Health Organization
grading classification (2010). The characteristics of the patients
studied (age, gender, and toxic habits) and the clinicopathologi-
cal features of their tumors (WHO classification, tumor site, size,
differentiation, stage, mitotic index, proliferation index, vascular
invasion, lymph node status, necrosis, and presence of metasta-
sis) were recorded. Tissues obtained from biopsies were fixed in
10% formaldehyde and paraffin embedded then cut in 4µm thick-
nesses, mounted on treated slides, and stained with Hematoxylin–
Eosin (H&E). The neuroendocrine phenotype was confirmed
by chromogranin A and synaptophysin immunohistochemical
staining. Normal tissue present in each tissue section was used
as a reference.
TISSUE MICROARRAY CONSTRUCTION
Representative tumor regions were identified in each sample
and selected to make a tissue microarray containing three tis-
sue cores from each of 31 GEP and 8 L-NETs. After 5 min at
60°C the blocks were cut into 4µm sections in preparation for
immunohistochemical techniques.
TOTAL RNA ISOLATION AND cDNA SYNTHESIS
To obtain the RNA, fragments of frozen tissue of between 20 and
30 mg in weight were used. Samples were homogenized using a
PT 2100 Polytron (Kinematica, Inc., Bohemia, NY, USA), and
RNA was isolated using the RNeasy kit, following the manufac-
turer’s specifications. To ensure removal of residual contaminating
DNA, samples were subjected to treatment with RNase-free DNase
during the purification process itself. The concentration of RNA
obtained was determined spectrophotometrically by measuring
absorbance using a Picodrop Microliter UV/Vis spectrophotome-
ter (Picodrop Limited, Frozen, UK). The samples were divided
into aliquots of 10µl and used for reverse transcription reactions
or stored at−20°C until further use.
cDNA synthesis was carried out using the High-Capacity cDNA
Transcription Kit following the manufacturer’s specifications. The
reactions were performed using an iCycler iQ PCR Thermal Cycler
(BioRad, Hercules, CA, USA), using 2µg of RNA as starting mate-
rial. The reaction products were cleaned using the PCR Clean-Up
GenElute kit following the manufacturer’s instructions. Finally,
the aliquots containing the cDNA were diluted 1:20 with water
and used for qRT-PCR assays or stored at−20°C until use.
qRT-PCR REACTIONS
In all cases, specific oligonucleotides were designed on different
exons or exon junctions, using the program Primer 31. The size
of the amplicon was situated in all cases between 70 and 150 bp,
ensuring wherever possible that the Tm was above 77°C. The the-
oretical Tm for each amplicon was determined using the program
Biomath2.
The primer sequences were: SDC1 (Gene ID 6382) forward
5′ CTCAGGTGCAGGTGCTTTG 3′, reverse 5′ CTGCGTGTC-
CTTCCAAGTG 3′; SDC2 (Gene ID 6383) forward 5′ GATGAC-
GATGACTACGCTTCTG 3′, reverse 5′ TGGAAGTGGTCGAGAT-
GTTG 3′; SDC3 (Gene ID 9672) forward 5′ CTCCTTTCC-
CGATGATGAAC 3′, reverse 5′ CGACTCCTGCTCGAAGTAGC
3′; SDC4 (Gene ID 6385) forward 5′ GGCAGGAATCT-
GATGACTTTG 3′, reverse 5′ TCTAGAGGCACCAAGGGATG
3′; GPC1 (Gene ID 2817) forward 5′ CATCGGGTGTGGA-
GAGTG 3′, reverse 5′ TGAGCGTGTCCCTGTTGTC 3′; GPC2
(Gene ID 221914) forward 5′ CTGGGACACGACCTGGAC
3′, reverse 5′ GCCATCCAGTCATCTGCATAC 3′; GPC3 (Gene
ID 2719) forward 5′ CTGCTTCAGTCTGCAAGTATGG 3′,
reverse 5′ GTGGAGTCAGGCTTGGGTAG 3′; GPC4 (Gene ID
2239) forward 5′ AGTGTGGTCAGCGAACAGTG 3′, reverse
1http://biotools.umassmed.edu/bioapps/primer3_www.cgi
2http://www.promega.com/techserv/tools/biomath/calc11.htm
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5′ CAAACATATCATTCAGGGATTTCTC 3′; GPC5 (Gene ID
2262) forward 5′ GCCGCCCTGTAAGAACAC 3′, reverse 5′
TCATTCCATGCTTCTCTTTGC 3′; GPC6 (Gene ID 10082) for-
ward 5′ CCAGGCATAAGAAATTTGACG 3′, reverse 5′ CATG-
TACAGCATGCCATAGGTC 3′; PRCAN (Gene ID 3339) forward
5′ TGGACACATTCGTACCTTTCTG 3′, reverse 5′ CACTGC-
CCAGGTCGTCTC 3′; AGRN (Gene ID 375790) forward 5′ ACT-
GTGTCTGCCCGATGC 3′, reverse 5′ GACACTCGTTGCCGTAT-
GTG 3′; COL18A1 (Gene ID 80781) forward 5′ GTACAAGGGA-
GAGATTGGCTTTC 3′, reverse 5′ TTTCTCTCCTTTCAATC-
CGTTC 3′; XYLT1 (Gene ID 64131) forward 5′ ACTACCC-
CATCAGGACAAATGA 3′, reverse 5′ CTGCTTCCGAATGAAC-
CTTG 3′; XYLT2 (Gene ID 64132) forward 5′ AGGGC-
CTGGTAGTGTGGAG 3′, reverse 5′ TGAACTGTCTGTGTC-
CTTGGAA 3′; FAM20B (Gene ID 9917) forward 5′ TCT-
GCAGAAGCACCGTCA 3′, reverse 5′ CAGCTGTGTCAATGAT-
GTCCA 3′; B4GALT7 (Gene ID 11285) forward 5′ GCGAG-
GACGACGAGTTCTAC 3′, reverse 5′ CAGGTGGCGAAAT-
GTCTTGTA 3′; B3GALT6 (Gene ID 126792) forward 5′
CACGTGGCCTTCGAGTTC 3′, reverse 5′ CCGAGAAGAAGC-
CCCAGTA 3′; B3GAT1 (Gene ID 27087) forward 5′ TGGT-
GAATGAGGGCAAGAA 3′, reverse 5′ CTTAGGAGTCGGC-
CTTGGA 3′; B3GAT2 (Gene ID 135152) forward 5′ GCT-
GACGACGACAACACCTA 3′, reverse 5′ CGGTGTACCAGCCAA-
CAAC 3′; B3GAT3 (Gene ID 26229) forward 5′ GAAGAACGT-
GTTTCTCGCCTAC 3′, reverse 5′ CCTCAGATCCTTCTGCCGTA
3′; EXTL2 (Gene ID 2135) forward 5′ TGAACTGGAAAC-
CAATGCAG 3′, reverse 5′ AGGAAATTGCTGCCAAACTG 3′;
EXTL3 (Gene ID 2137) forward 5′ CTCCGCCATGACGAAATC
3′, reverse 5′ AGTTGGAGTTGTAGAGCCAGGA 3′; CSGAL-
NACT1 (Gene ID 55790) forward 5′ GGAGACCCTGAA-
CAATCCTG 3′, reverse 5′ GCCGTTTGAATTCGTGTTTG 3′;
CSGALNACT2 (Gene ID 55454) forward 5′ GCCATTGTT-
TATGCCAACCA 3′, reverse 5′ ATCCACCAATGGTCAGGAAA
3′; CHSY1 (Gene ID 22856) forward 5′ GCCCAGAAATAC-
CTGCAGAC 3′, reverse 5′ CACTACTGGAATTGGTACAGATG
3′; CHPF (Gene ID 79586) forward 5′ CTGGGTCGCT-
GCATTCTC 3′, reverse 5′ GGCACTTCGGAAATGAGG 3′;
CHSY3 (Gene ID 337876) forward 5′ CGCCGACGACGATGTC-
TAC 3′, reverse 5′ CCAGTCCCAGCTTTCCAAG 3′; CHST11
(Gene ID 50515) forward 5′ CGCTGCTGGAAGTGATGA 3′,
reverse 5′ CAGCAGATGTCCACACCAA 3′; CHST12 (Gene ID
55501) forward 5′ GTAGCCGACAAATCCTTCCA 3′, reverse
5′ ACCGGTTTACCTCTGACTTGAC 3′; CHST13 (Gene ID
166012) forward 5′ CCGGCATTTGGAAACAGA 3′, reverse
5′ TCCAGGTCATAGAGCTTCTGC 3′; CHST14 (Gene ID
113189) forward 5′ CCACTGCCTAATGTCACCAA 3′, reverse 5′
ATGACAGGCAGAAGCACAGA 3′;CHST15 (Gene ID 51363) for-
ward 5′ GTGCCAGGAATAAAGTTCAACA 3′, reverse 5′ CACTG-
GATAAGTCCCGAGTGA 3′; CHST3 (Gene ID 9469) forward 5′
TGCACAGCCTGAAGATGAGA 3′, reverse 5′ CAGCTTGTCTGA-
GACCCTTGA 3′; CHST7 (Gene ID 56548) forward 5′ GATC-
CGGGTCAGTCACCA 3′, reverse 5′ GACAGATTGCCCCCACAG
3′; DSE (Gene ID 29940) forward 5′ GTCCAGAGGCACTTCAA-
CATC 3′, reverse 5′ AGTCCGCAATAGCCACAGTC 3′; and UST
(Gene ID 10090) forward 5′ ACCATGGACCACCTCCTAGTAA 3′,
reverse 5′ GCTTCTCCGACAAGATTCTCA 3′.
At least four repetitions of each qRT-PCR reaction were carried
out in a final volume of 10µl, according to the manufacturer’s
specifications, using 1µl of the cDNA dilution as template, with
2µl of primer pair mix (200 nM final concentration) and 5µl of
SYBR Green mix, contained in 96 well microtiter plates. The plates
were sealed with optical film and centrifuged at 2500 rpm for 5 min
before being placed in a Real-Time ABI Prism Detection System
device (Applied Biosystems, Foster City, CA, USA) using the fol-
lowing cycling conditions: 95°C for 10 min, 40 cycles of 95°C for
15 s followed by 60°C for 60 s. Following thermal cycling and data
collection steps, amplimer products were analyzed using a melt
curve program (95°C for 1 min, 55°C for 1 min, then the temper-
ature was increased by 0.5°C per cycle for 80 cycles of 10 s each).
For each amplification the presence of a single peak with a Tm
corresponding to that previously calculated was verified. In those
cases in which the amplifications were not adequate, new primer
pairs were designed. Actin was included on each plate as a control
gene to compare run variation and to normalize individual gene
expression.
DATA ANALYSIS
To calculate the efficiency of amplification for each gene we used
the program LinRegPCR3, using the best correlation coefficient
(considering a minimum of three points within the window of
linearity) and establishing the average of all positive amplifi-
cations. At least four replicates of each reaction were carried
out, with the number of replicates being increased in those
reactions that showed ambiguity or dispersion of results. The
values of differential expression of the genes of interest were
expressed according to the equation below, as has been described
previously (20).
rER = (1+ E (GOI ))−∆Ct(GOI )/(1+ E (HKG)) −∆Ct(HKG)
with ∆C t (gene)=∆C t (gene, well-differentiated)−∆C t (gene,
poorly differentiated). Here, rER is the relative expression ratio
of a gene-of-interest GOI (relative to a housekeeping gene
HKG).
IMMUNOHISTOCHEMISTRY
Tissue sections were dewaxed as described in the previous section.
Rehydrated sections were rinsed in phosphate buffered saline
(PBS) containing 1% tween-20. Sections were heated in High pH
EnVision FLEX Target Retrieval Solution at 65°C for 20 min and
then incubated for 20 min at room temperature in the same solu-
tion. Endogenous peroxidase activity (3% H2O2) and non-specific
binding (33% fetal calf serum) were blocked and the sections
were incubated overnight at 4°C with primary antibodies using a
1:100 dilution. Secondary antibodies were used at a 1:100 dilution.
3,3′-diaminobenzidine was used as a chromogen. Finally, samples
were counterstained with hematoxylin, dehydrated and mounted
in Entellan® (Merck, Germany). The sections were studied and
photographed (20× and 40× objective) under a light microscope
(Nikon – Eclipse 80i).
3http://www.gene-quantification.de/download.html
Frontiers in Oncology | Molecular and Cellular Oncology February 2014 | Volume 4 | Article 15 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
García-Suárez et al. Proteoglycan alterations in neuroendocrine tumors
IMMUNOHISTOCHEMISTRY ASSESSMENT
The protein expression levels were evaluated by two indepen-
dent observers (and a third in cases of disagreement) taking into
account two parameters: immunohistochemical signal intensity
(in a 0–3 point scale) and the percentage of positive cells (0–100).
For statistical purposes, the tumors were divided into two groups
taking the median score value for each marker as a cutoff point.
STATISTICAL ANALYSIS
All analyses were performed using the Statistics for Windows pro-
gram (StatSoft, Inc., Tulsa, OK, USA). Mean values were compared
between two samples by the Mann–Whitney U test and between
multiple samples by the Kruskal–Wallis test. Correlations were
assessed by Pearson’s correlation coefficient. p< 0.05 was accepted
as significant.
RESULTS
ANALYSIS OF DIFFERENTIAL GENE EXPRESSION
We investigated the differential expression of two specific families
of genes involved in the biosynthesis of PGs in NETs: HSPG core
proteins and CS biosynthesis enzymes. Firstly,we used qRT-PCR to
perform a quantitative analysis of the differential transcription of
the coding genes using eight samples of lung NETs. Poorly differ-
entiated large cell NETs were analyzed, and compared to low-grade
well-differentiated typical carcinoids. The samples corresponded
to patients of both sexes, aged between 49 and 84 years.
Determining the expression of the different proteins or saccha-
ride chains of the GAGs analyzed was performed by immunohisto-
chemistry using a tissue array in which tumor and healthy samples
of 39 patients were included (Table 1). The array included nine
specimens of small intestine NETs, six pancreatic, one esophageal,
eight from the colon, four from the stomach, one hepatic, two
from the appendix, and eight from the lung. Twenty samples cor-
responded to well-differentiated and 19 to poorly differentiated
tumors. Eleven of the tumor samples were in stage 1, 7 in stage 2,
14 in stage 3, and 7 in stage 4. The distribution of patients’ ages at
diagnosis was as follows; 8 were aged between 39 and 49 years, 3
between 50 and 59, 16 between 60 and 69, 9 between 70 and 79,
and 3 were over 80.
DIFFERENTIAL EXPRESSION OF HSPG CORE PROTEINS
Only 13 genes encode HSPG core proteins. Two gene families,
syndecans and glypicans, account for most cell surface HSPGs.
Respectively these families comprise 4 (SDC1–4) and 6 (GPC1–
6) different proteins. The three remaining molecules are arranged
in the ECM and include perlecan (PRCAN), agrin (AGRN), and
collagen type 18 (COL18A1) (21).
When we analyzed the levels of transcription of these genes
in well-differentiated and poorly differentiated lung tumors by
means of qRT-PCR, there were no significant differences in any
of the ECM PGs (Figure 2A). However, the cell surface HSPGs
showed some significant differences. Within the group of synde-
cans, no significant differences in the levels of transcripts of iso-
forms 1, 3, and 4 could be detected (Figure 2A). However, synde-
can 2 levels were significantly different; decreasing approximately
14-fold in high-grade tumors (Figure 2B).
Changes in the expression of syndecan 2 in NETs were eval-
uated by immunohistochemistry using tissue arrays with tumors
Table 1 | Patient demographics, histologic grade, and staging.
Patient no. Age Sex Location Grade Stage Differentiation
1 81 F Ileum G3 T3 PD
2 40 F Pancreas G3 T4 PD
3 76 M Esophagus G3 T3 PD
4 44 M Colon G1 T3 WD
5 66 M Ileum G1 T3 WD
6 76 M Stomach G3 T3 PD
7 66 M Ileum G1 T3 WD
8 49 M Liver G1 T2 WD
9 63 M Appendix G1 T1 WD
10 40 F Pancreas G2 T4 PD
11 48 M Pancreas G1 T1 WD
12 61 M Colon G1 T2 WD
13 73 F Colon G1 T2 WD
14 60 F Ileum G1 T4 WD
15 62 M Appendix G1 T1 WD
16 65 M Pancreas G3 T3 PD
17 60 M Colon G3 T3 PD
18 62 F Jejunum G1 T3 WD
19 71 M Ileum G1 T3 WD
20 69 M Stomach G1 T3 PD
21 74 M Stomach G3 T2 PD
22 52 M Jejunum G3 T3 PD
23 55 M Ileum G1 T2 WD
24 70 M Pancreas G1 T2 WD
25 70 M Colon G3 T4 PD
26 77 M Stomach G3 T4 PD
27 64 F Ileum G1 T1 WD
28 42 M Colon G2 T4 PD
29 64 F Colon G3 T4 PD
30 87 F Colon G2 T1 PD
31 71 F Pancreas G1 T1 WD
32 66 M Lung G2 T2 PD
33 49 F Lung G3 T3 PD
34 67 M Lung G2 T1 PD
35 65 M Lung G3 T3 PD
36 63 M Lung G1 T1 WD
37 51 F Lung G1 T1 WD
38 84 M Lung G1 T1 WD
39 49 M Lung G1 T1 WD
WD, well-differentiated; PD, poorly differentiated.
of different origins, grades, and cell differentiation, as detailed
above. Labeling with anti-syndecan 2 was very low or undetectable
in normal tissues, increasing significantly in well-differentiated
tumors, and decreasing in poorly differentiated NETs (Figure 3).
Semiquantitative analysis of expression levels in normal tissues
and in well- and poorly differentiated tumors allowed significant
differences between them to be determined (p= 0.05, Kruskal–
Wallis test); specifically between healthy and tumor tissues, either
well- or poorly differentiated (p< 0.0001 and p= 0.003 respec-
tively, Mann–Whitney test), although there was a reduced level
of significance between the two tumor subgroups (p= 0.051)
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FIGURE 2 | Differential transcription of genes encoding HSPGs.
(A) Relative transcript abundance of mRNAs for HSPGs. Relative
abundance for well-differentiated lung NETs (gray bars) and poorly
differentiated lung NETs (black bars) are plotted on a log scale for each
gene assayed and the spread represents standard deviation. Genes
showing significant differences are indicated: 1, p<0.001; 2, p=0.018; 3,
p=0.0001. (B) Relative expression ratio of genes that show statistically
significant differences in expression in poorly differentiated compared to
well-differentiated tumors. Values on theY axis are represented on a
logarithmic scale.
(Figure 4A). When the syndecan 2 semiquantitative expression
levels in the different tumors were analyzed in relation to their
diagnosis features, there was a significant correlation with tumor
grade (r Spearman −0.47, p= 0.004) (Figure 4B) although the
correlation was not significant in terms of tumor stage (p= 0.2)
(Figure 4C). Interestingly, there was also a good positive corre-
lation between syndecan 2 levels and patient survival (r s= 0.6,
p= 0.004). The cases presenting higher levels of this PG displayed
better prognosis. In addition, we quantified the existence of cor-
relations between syndecan 2 expression and tumor topography
using the classical division into foregut, midgut, and hindgut (22),
although no positive relationship was found (p= 0.85).
Analysis of the expression levels of the different glypicans
showed substantial differences between them, far greater than in
the syndecans, with the differences reaching up to two orders of
magnitude. The qRT-PCR studies performed on well- and poorly
differentiated lung NETs showed significant differences for two
of the six species, glypican 1 and 5 (Figure 2). Transcripts of both
genes evidenced a decreased expression in high-grade tumors, esti-
mated at around 70% in the case of glypican 1 and about 230-fold
for glypican 5.
Analogously to syndecan 2, glypican 1 expression was analyzed
by immunohistochemistry using tumor tissue arrays. Expression
of glypican 1 could be determined in normal tissues, but its magni-
tude increased strongly in well-differentiated tumors. By contrast,
the expression of this protein dramatically decreased in high-grade
NETs, reaching undetectable levels (Figure 5). Semiquantitative
analysis of expression levels in normal tissues and in tumors
showed significant differences between them (p< 0.0001); the dif-
ferences being most marked when comparing high-grade tumors
with normal tissue or well-differentiated tumors (p< 0.0001 in
both cases), but they were also significant for the notable increase
in expression when comparing normal tissue and low-grade
tumors (p= 0.01) (Figure 6A). Furthermore, analysis of the glyp-
ican 1 expression levels in the different tumors in relation to their
diagnosis features showed a significant negative correlation with
tumor grade (r s=−0.74, p< 0.0001), reflecting the disappear-
ance of the expression in tumors of grade 2 or higher (Figure 6B).
The correlation was more complex with respect to tumor stage
(r s=−0.33, p= 0.43) since expression increased in tumors up
to stage 2, and then decreased progressively at higher stages
(Figure 6C). Also, there was a positive correlation between the
expression levels of glypican 1 and patient survival, albeit some-
what lower than the values determined for syndecan 2 (r s= 0.54,
p= 0.01). Furthermore, analysis of protein expression based on
topography of the tumor showed no positive relationship to exist
(p= 0.17).
The expression of glypican 5 was also analyzed at the protein
level by immunohistochemistry. We were not able to detect posi-
tive results in the majority of normal tissues (Figure 7), although
about 25% of the analyzed samples showed staining in neuroen-
docrine cells (Figure 7). Moreover, only 16% of low-grade tumors
exhibited a positive reaction, most showing an absence of staining
(Figure 8). Surprisingly, and in contrast to the data obtained for
differential transcription, glypican 5 appeared overexpressed in
70% of high-grade tumors (Figure 8). High-grade tumors over-
expressing the protein showed a characteristic phenotype, with
epithelial differentiation, whereas those in which the molecule was
not detected displayed a neuroendocrine phenotype (Figure 8).
Semiquantitative analysis of expression levels allowed the observed
differences to be determined as statistically significant (p= 0.001,
Kruskal–Wallis test); specifically between well- and poorly dif-
ferentiated tumors (p= 0.007, Mann–Whitney test) (Figure 9A).
Furthermore, analysis of glypican 5 protein expression in relation
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FIGURE 3 | Immunohistochemical staining of syndecan 2 in NETs.
(A,D,G,J) Normal tissue from colon (A), lung (D), small intestine (G),
and gastric transitional mucosa (J). (B,E,H,K) Well-differentiated NETs
from colon (B), lung (E), small intestine (H), and pancreas (K).
(C,F,I,L) Poorly differentiated NETs from colon (C), lung (F), stomach (I),
and pancreas (L). Syndecan 2 antibody marks normal epithelial cells,
namely intracryptic cells, with faint cytoplasmic staining. The marking is
enhanced in low degree NETs, decreasing in those NETs with the
highest degree of malignancy (neuroendocrine carcinomas).
Magnification 200×.
FIGURE 4 | Quantification of immunochemical staining of syndecan 2. (A) Relative to the tumor differentiation. (B) Relative to tumor grade. (C) Relative to
tumor stage. Semiquantitative scale from 0 to ++ was used. Vertical bars denote 0.95 confidence intervals.
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FIGURE 5 | Immunohistochemical staining of glypican 1 in NETs.
(A,D,G,J) Normal tissue from colon (A), lung (D), small intestine (G),
and gastric transitional mucosa (J). Arrows indicate neuroendocrine
cells. (B,E,H,K) Well-differentiated NETs from colon (B), lung (E), small
intestine (H), and pancreas (K). (C,F,I,L) Poorly differentiated NETs
from colon (C), lung (F), stomach (I), and pancreas (L). Low-grade
tumors exhibited markedly increased staining compared to normal
tissue in both cytoplasm and cell membrane. By contrast, high-grade
tumors showed a drastic decrease in expression. Magnification
200×.
to diagnosis features showed a significant level of positive cor-
relation with tumor grade (r s= 0.43), reflecting the increase in
expression in tumors of grade 2 or higher (Figure 9B), as well as
with respect to tumor stage (r s= 0.48) since expression increased
in tumors of stages 3 and 4 (Figure 9C). In contrast, there was no
significant correlation between the expression levels of glypican 5
and patient survival (r s=−0.32), and analysis of protein expres-
sion based on the topography of the tumor showed no positive
relationship exists (p= 0.11).
DIFFERENTIAL EXPRESSION OF CHONDROITIN SULFATE CHAINS
Chondroitin sulfate is an anionic linear polysaccharide that is
implicated in cancer through its involvement in many essential
aspects of cell physiology. The synthesis of CS chains initially
requires an array of glycosyltransferases (GTs), which generate
a tetrasaccharide glycan linker on a cognate serine residue of
the PG core. This linker is shared by CS and HS chains and its
sequence is integrated by xylose–galactose–galactose–GlcA (10).
CS chain extension requires the subsequent transference of a
GalNAc residue, followed by the sequential addition of alternating
GlcA and GalNAc residues to generate a non-branched polymer.
By contrast, the addition of GlcNAc rather than GalNAc directs the
pathway toward the biosynthesis of HS. In this case, chain exten-
sion takes place through the sequential addition of alternating
GlcA and GlcNAc residues (10, 16).
We analyzed the differential transcription of seven GTs involved
in the biosynthesis of the tetrasaccharide linker, XYLT1 and
XYLT2, responsible for the initial transfer of xylose residues,
B4GALT7 and B3GALT6, which encode the enzymes responsi-
ble for the sequential addition of the two residues of galactose,
and B3GAT1, B3GAT2, and B3GAT3, responsible for the trans-
fer of the GlcA residue at the end of the linker (23). It proved
possible to measure amplifications of transcripts of all these
genes except for B3GAT2. Additionally, three of these transcripts
displayed a significant subexpression in poorly differentiated
lung tumors compared to well-differentiated ones (Figure 10A).
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FIGURE 6 | Quantification of immunochemical staining of glypican 1. (A) Relative to tumor differentiation. (B) Relative to tumor grade. (C) Relative to tumor
stage. Semiquantitative scale from 0 to +++ was used. Vertical bars denote 0.95 confidence intervals.
FIGURE 7 | Immunohistochemical staining of glypican 5 in
normal tissues. (A,B,D,E) Normal tissues not expressing GPC5 from
colon (A), small intestine (B), gastric transitional mucosa (D), and
lung (E). (C,F) Normal tissues displaying positive reaction in
neuroendocrine cells from small intestine (C), and lung (F).
Magnification 400×.
XYLT1,B3GAT1, and B3GAT3 were downregulated around 7-, 22-,
and 3-fold respectively (Figure 10B).
Alterations in the transcription of the five genes involved in
the polymerization of CS chains (CSGALNACT1, CSGALNACT2,
CHSY1, CHPF, and CHSY3) were also studied. Under-expression
was detected in two, CSGALNACT1 and CHPF, in high-grade
compared to well-differentiated NETs, and in both cases the
deregulation was around threefold (Figure 10).
Finally, given that the synthesis of CS chains takes place in
competition with the synthesis of HS, we analyzed the two GTs
responsible for transferring the first GlcNAc residue (EXTL2 and
EXTL3), along with the xylose kinase involved in the regula-
tion of HS biosynthesis (FAM20B) (24). We were only able to
detect a deregulation of the kinase, which was downregulated
approximately 2.5-fold (Figure 10).
The result of the action of all GTs involved in the synthesis
of CS is an unmodified chain that consists simply of repeating
GalNAc–GlcA units. As the chain polymerizes, it undergoes a series
of modifications that include the epimerization of GlcA in CS
chains, which results in DS chains, catalyzed by DSE; the addi-
tion of sulfate groups at C2 of IdoA residue of DS, catalyzed by
chondroitin uronosyl sulfotransferase (UST); sulfation at C4 of
GalNAc, catalyzed by different isoenzymes with specificity for CS
or DS chains (CHS11, CHS12, CHS13, and CHS14); addition of
sulfate at C6 of GalNAc, also catalyzed by different isoenzymes
(CHS3 and CHS7); and sulfation at C6 can also occur in pre-
sulfated residues catalyzed by a N -acetylgalactosamine 4-sulfate
6-O-sulfotransferase (CHS15) (Figure 1) (23). The analysis of the
differential transcription of these genes in high-grade compared
to low-grade tumors showed significant differences for only two
www.frontiersin.org February 2014 | Volume 4 | Article 15 | 9
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FIGURE 8 | Immunohistochemical staining of glypican 5 in
NETs. (A,B,D,G,J) Well-differentiated NETs; tumors not
expressing GPC5 from colon (A), lung (D), small intestine (G) and
pancreas (J), and displaying positive reaction from colon (B).
(C,E,F,H,I,K,L) Poorly differentiated NETs; tumors showing positive
reaction from colon (C), lung (F), stomach (I) and pancreas (L), and
not expressing GPC5 from colon (E), lung (H) and stomach (K).
Magnification 200×.
FIGURE 9 | Quantification of immunochemical staining of glypican 5. (A) Relative to tumor differentiation. (B) Relative to tumor grade. (C) Relative to tumor
stage. Semiquantitative scale from 0 to +++ was used. Vertical bars denote 0.95 confidence intervals.
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FIGURE 10 | Differential transcription of genes encoding enzymes
involved in the biosynthesis of CS repeating unit. (A) Relative
transcript abundance of mRNAs for CS biosynthesis. Relative
abundance for well-differentiated lung NETs (gray bars) and poorly
differentiated lung NETs (black bars) are plotted on a log scale for each
gene assayed and spread represents standard deviation. Genes
showing significant differences are indicated: 1, p=0.04; 2, p=0.03; 3,
p=0.003; 4, p=0.01; 5, p=0.02; 6, p=0.03; 7, p=0.01; 8, p=0.01.
(B) Relative expression ratio of genes that show statistically significant
differences in expression in poorly differentiated compared to
well-differentiated tumors. Values on theY axis are represented on a
logarithmic scale.
of them: CHST3, whose transcription was downregulated around
seven times, and UST, which showed a sevenfold overexpression
(Figure 10).
The combined action of all the above genes results in CS chains
with specific patterns of sulfation. Changes in the expression of
CS chains in NETs were evaluated by immunohistochemistry using
tissue arrays, as indicated above, and monoclonal anti-CS antibod-
ies. Antibodies applied to normal tissue sections showed faint stro-
mal staining, which was also present in isolated intestinal epithelial
cells. However, in well-differentiated NETs we found focal stromal
staining, which was clearly enhanced in the cases of the highest
grades (Figure 11). Semiquantitative analysis of expression levels
in normal tissues and in well- and poorly differentiated tumors
allowed the existence of significant differences between healthy
and well-differentiated NETs (p< 0.01) and healthy and poorly
differentiated NETs (p< 0.0001), but not between high-grade and
low-grade tumors (p= 0.46) to be determined (Figure 12A). In
the tumor samples there were no significant correlations between
level of expression of CS and tumor grade or stage (p= 0.5 and
p= 0.34 respectively), although these correlations did become
significant when expression levels in normal tissues were also con-
sidered (p= 0.0002 in both cases) (Figures 12B,C). Moreover,
no positive correlation was observed between the expression of
CS and either patient survival (p= 0.6) or location of the tumor
(p= 0.97).
DISCUSSION
Unlike other tumor types such as lung cancer or breast cancer,
which are defined by their tissue of origin, NETs arise from a
cell type, and may have originated in many parts of the body,
although GI and lung tumors account for around 90% of all
cases. Although some of the clinical and pathological features of
these tumors are specific to the organ of origin, other attributes
are shared by all these neoplasms and there are many similarities
among NETs throughout the body (4). Taking into account their
characteristics, NETs can be classified based on different criteria,
such as neoplasm grade, presence of associated secretory symp-
toms, and anatomical site of origin or histology. The histological
classification is widely accepted and divides the tumors into well-
and poorly differentiated. On the other hand, classification based
on anatomical location has usually divided tumors into foregut,
midgut, and hindgut, but raises some controversies, such as the
heterogeneity in the 5-year survival rates of the foregut neoplasms,
since cancers of the biliary system and pancreas are included in this
group (4, 22). Because of their diversity, NETs pose a major clinical
challenge, both in diagnosis and treatment if surgery is not feasible
(22).
Proteoglycans are critical in regulating the activity of many
signaling pathways, as well as cell–microenvironment interac-
tions. The development of cancer typically involves distinct stages,
including transformation, invasion and metastasis, and as a result
of their diverse functions, PGs and their GAG chains have been
found to be involved in tumorigenesis in several cancers, includ-
ing breast, lung, brain, pancreatic, and colorectal. Many studies
suggest that PGs regulate multiple oncogenic pathways in tumor
cells and promote critical tumor–microenvironment interactions,
such that these molecules are potentially important tumor markers
and therapeutic targets (15).
More than 50 members of the PG family have been charac-
terized and furthermore, many dozens of different enzymes have
been found to be responsible for the synthesis and editing of GAG
chains, including GTs, deacetylases, N - and O-sulfotransferases,
epimerases, sulfatases, kinases, or hydrolases, besides enzymes
involved in the synthesis and transport of precursors (12, 23, 24).
We focused this study on two specific groups of genes whose alter-
ations are particularly relevant in other tumor models previously
described; the HSPG core proteins and the enzymes involved in
the biosynthesis of CS chains.
In human cells, there are 13 genes encoding full-time HSPGs,
although a few more may appear as part-time ones (10, 25). Of
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FIGURE 11 | Immunohistochemical staining of CS in NETs.
(A,D,G,J) Normal tissue from colon (A), lung (D), small intestine
(G), and gastric transitional mucosa (J). (B,E,H,K) Well-differentiated
NETs from colon (B), lung (E), small intestine (H), and pancreas (K).
(C,F,I,L) Poorly differentiated NETs from colon (C), lung (F), stomach
(I), and pancreas (L). Normal tissue samples displayed faint stromal
staining, also present in isolated intestinal epithelial cells (A,D,G,J);
well-differentiated NETs showed focal stromal staining (B,E,H,K),
clearly enhanced in the cases of poorly differentiated tumors (C,F,I,L).
Magnification 400×.
the three ECM proteins studied, none showed alterations between
high- and low-grade lung NETs. In several tumor models alter-
ations in some of these genes have been described, particularly
in perlecan, which is fundamental for the maintenance of base-
ment membrane homeostasis (26), suggesting that its alteration
could play an important role in NET progression. Nevertheless,
we must consider that this differential transcription study analyses
differences in expression between well- and poorly differentiated
tumors, and not those that may have occurred as a consequence
of tumor transformation. However, in some tumors alterations in
expression levels of perlecan have been described, not only in rela-
tion to normal tissue, but also depending on the stage of tumor
progression (27).
Two gene families, syndecans and glypicans, account for most
cell surface HSPGs. Syndecans are a family of type 1 trans-
membrane proteins that comprises four members (SDC1–4).
In the syndecans group, only SDC2 transcripts appeared to be
downregulated, approximately 14-fold in high-grade-relative to
well-differentiated tumors. At the level of protein expression,
analysis of various tumors by immunohistochemistry revealed
an overexpression in low-grade tumors compared to normal tis-
sues, which showed very low or undetectable levels, and a decrease
in high-grade tumors, although apparently less intense than that
determined for mRNA. Syndecans act as cell surface receptors but,
in contrast to other types of receptors that interact with a limited
number of ligands, they can interact with many extracellular mol-
ecules, including different types of soluble and insoluble proteins,
lipids, and even microorganisms; this allows them to play a dual
role as both adhesion receptors and docking receptors (28).
Overexpression of SDC2 has been previously described in some
malignances, including Lewis lung carcinoma, ovarian and brain
tumors, mesothelioma, osteosarcoma, and colon cancer (29–33).
In this study, SDC2 expression was not influenced by the location
of the tumor (foregut, midgut, or hindgut), suggesting that it is
Frontiers in Oncology | Molecular and Cellular Oncology February 2014 | Volume 4 | Article 15 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
García-Suárez et al. Proteoglycan alterations in neuroendocrine tumors
FIGURE 12 | Quantification of immunochemical staining of CS. (A) Relative to tumor differentiation. (B) Relative to tumor grade. (C) Relative to tumor stage.
Semiquantitative scale from 0 to +++ was used. Vertical bars denote 0.95 confidence intervals.
a common feature of these neoplasms throughout the body and
that their size or spread do not significantly influence the expres-
sion of this protein. It has been proposed that this molecule plays
an important role in promoting tumorigenesis and angiogenesis.
As such, in colorectal cancer and Lewis lung carcinoma SDC2 can
promote tumorigenesis by acting on the regulation of cell adhe-
sion, spreading, and cytoskeletal organization (29, 30). In addition,
its role in angiogenesis is supported by various data such as its high
expression in the microvasculature of mouse glioma tumors (31),
or its essential role in the sprouting of new blood vessels dur-
ing zebrafish embryogenesis (34) and in many steps of human
“in vitro” neovascularization (35). Interestingly, however, in the
tumors analyzed in this work there was a good positive correlation
between SDC2 levels and patient survival, data that has also been
described in esophageal squamous cell carcinoma, prostate cancer,
and pancreatic ductal adenocarcinoma, leading to the proposal
that the expression levels of this molecule are of interest for diag-
nosis (36–38). These observations can be related to data suggesting
a role for this PG as a metastasis inhibitor; thus a highly metastatic
variant of Lewis lung carcinoma cells displays low SDC2 expres-
sion, and this molecule is able to suppress activation of matrix
metalloproteinase-2 (39); Furthermore, it has been described that
osteosarcoma cells that overexpress SDC2 are restricted in their
migration and also exhibit enhanced apoptosis in vitro (40). There-
fore it would appear that the role that SDC2 plays is complex and
depends on the type of tumor and microenvironmental factors.
The glypicans constitute a six-member family of cell surface
PGs that are glycosylphosphatidylinositol (GPI)-linked to the cell
membrane. Their expression is cell type and developmental-stage-
specific and they are involved in fundamental biological processes
including cell division, interactions with ECM, differentiation, and
morphogenesis (33). At the level of signaling, they are implicated in
the regulation of several pathways, where they can either stimulate
or inhibit activity depending on the biological context. These path-
ways include Wnts, Hedgehogs, FGF, bone morphogenic protein,
and insulin-like growth factor (41). The analysis of the expression
of the six protein isoforms in well- and poorly differentiated lung
tumors by means of qRT-PCR showed approximately threefold
derregulations for GPC1 and about 230-fold for GPC5; none of
the other species displayed significant differences. It is of note that
GPC1, 3, and 5 have been implicated in the tumorigenic process,
mostly affecting growth-factor signaling and cell proliferation.
In adults, GPC5 is primarily expressed in the brain, and it is
also detected in fetal brain, lung, and liver. In well-differentiated
NETs, GPC5 mRNA shows the highest level of transcription rela-
tive to the other glypican isoforms, but this transcription declines
dramatically in poorly differentiated tumors. Surprisingly, analy-
sis of the expression of GPC5 at the protein level, performed
by immunohistochemistry, revealed that only a small proportion
of normal tissues and well-differentiated tumors showed a pos-
itive reaction, whereas the protein was overexpressed by 70% of
high-grade tumors. Furthermore, there were some phenotypic dif-
ferences between poorly differentiated tumors expressing the pro-
tein, which displayed epithelial differentiation, and those that did
not, which showed a neuroendocrine phenotype. Previous studies
have reported low correlations between mRNA levels and pro-
tein expression in many genes, suggesting different mechanisms
are responsible for the observed differences in the quantitative
relation between transcriptome and translatome (42). In studies
of lung adenocarcinoma it has been described that the majority
of genes analyzed (16/21) the protein/mRNA correlation did not
differ between stages 1 and 3 tumors, indicating a similar regu-
latory relationship between mRNA and protein. However, some
genes (5/21) did show significant differences in correlation coef-
ficients between stages 1 and 3 lung adenocarcinomas, and for
3 of these the change was because of a relative increase in pro-
tein expression in stage 3 tumors (43). In addition, other studies
in various tumors such as bladder cancer, show good correlation
between transcript alterations and protein levels, albeit with a few
exceptions, which have shown disagreement between transcript
alteration and protein alteration (44). These data indicate that in
the expression of GPC5 in NETs additional post-transcriptional
mechanisms, such as protein translation, degradation, inhibition
by feedback loops, or miRNA regulation may be involved. The
data obtained in the current work at the protein level demonstrat-
ing that high-grade tumors display epithelial differentiation are
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consistent with those previously described for lymphoma, where
overexpression of this gene may contribute to the development and
progression of the tumor (45), and rhabdomyosarcoma (primarily
pediatric sarcomas resembling developing skeletal muscle) where
GPC5 is upregulated and strongly associated with the appearance
of and increase in cell proliferation (46). Our data show GPC5
protein expression to be correlated with tumor grade, increasing
in tumors of grade 2 or higher, and with tumor stage, increasing
in tumors of stages 3 and 4, but not with patient survival or the
topography of the tumor.
With regard to GPC1, immunohistochemical studies show
strong expression levels in well-differentiated NETs, which
decreases drastically and disappears altogether in poorly differenti-
ated ones. As with SDC2 and GPC5, expression was not influenced
by the location of the tumor, suggesting that this is another com-
mon feature shared by all neoplasms,wherever they are in the body.
However, when transcription levels of the gene were analyzed,
poorly differentiated tumors displayed mRNA levels of around
30% of those present in well-differentiated NETs. This discrep-
ancy again suggests the existence of other, overlapping, levels of
regulation, possibly at the level of translation; as such, the exis-
tence of translation-level regulation has been described in some
genes involved in the biosynthesis of GAGs and PGs (47–49).
GPC1 expression correlated well with tumor grade, and showed
some degree of positive relationship with patient survival, which
suggests it has possible uses as a prognosis factor.
GPC1 overexpression has been described in certain tumors,
although with some peculiarities depending on the neoplasia. This
isoform shows increased expression in gliomas, where it acts to
enhance FGF signaling and mitogenesis (50); in pancreatic can-
cer GPC1 is strongly expressed both by the cancer cells and the
adjacent fibroblasts, whereas its expression is low in the nor-
mal pancreas (51); in breast cancer GPC1 expression is strong in
high-grade tumors (52), whilst in prostate cancer high expression
occurs in tumor stroma although it disappears in tumor epithelial
cells (53).
Although GPC3 is the species for which most expression alter-
ations in tumors have been described, it does not appear to
undergo alterations in NETs in relation to the degree of cell dif-
ferentiation. Unlike isoforms 1 and 5, whose alterations involve
increased protein expressions associated with carcinogenesis, vari-
ations in GPC3 expression levels vary greatly depending on the
type of neoplasm (33, 41). Downregulation of GPC3 has been
described in many tumor types, including breast, lung, gastric,
and ovarian cancers and mesothelioma (41). However, in tumors
originating from tissues that only express GPC3 in the embryo, its
expression tends to appear with malignant transformation (41).
The effects of loss of GPC3 on tumor development are compatible
with its function as a tumor suppressor, since this molecule is an
inhibitor of cell proliferation and can induce apoptosis (54). How-
ever, GPC3 overexpression can act as an oncogene in some tumors,
such as hepatocellular carcinomas (55). It is worth noting that, in
this work, we report a decrease in the expression of GPC1 and an
increase in GPC5 with increasing tumor grade, suggesting that the
involvement of these molecules in cancer, as in the case of GPC3,
may range from tumor suppressors to oncogenes depending on
tumoral context.
Most, if not all, HSPGs can be hybrid molecules, carrying
both HS and CS side chains (21), besides specific CSPG mol-
ecules that can be located in the extracellular space, at the cell
surface and also intracellularly (12). CS chains regulate key cel-
lular processes, including ECM assembly, proliferation, apoptosis,
migration, adhesion, invasion, and metastasis, and their molecular
structures are among the most widely and most frequently altered
in cancer (12, 56). Both HS and CS chain biosynthesis begins
with the generation of a tetrasaccharide linkage on specific accep-
tor serine residues of a PG core protein. At this point, there are
two competing paths: toward the synthesis of CS or HS, depend-
ing on the addition of a GalNAc or a GlcNAc residue. Finally,
CS chains are elongated by the addition of alternating GlcA and
GalNAc residues. Analyzing the differential transcription of all
genes involved in this process in well-differentiated tumors com-
pared to poorly differentiated,we found downregulation ofXYLT1,
responsible for the initial transfer of xylose residue, B3GAT1, and
B3GAT3, responsible for the transfer of the first GlcA, CSGALN-
ACT1, one of the genes that directs biosynthesis toward CS chains,
and CHPF, involved in CS polymerization. Taken together, these
data indicate a decrease in the synthesis of CS chains in poorly
differentiated tumors. This conclusion is reinforced by the lack of
alteration in the enzymes responsible for the initiation of the syn-
thesis of HS EXTL2 and EXTL3, which acts in competition with CS
biosynthesis. In addition, during synthesis of the linkage region, a
transient phosphorylation of the xyl residue occurs, catalyzed by a
xylose kinase (encoded by FAM20B), which is dephosphorylated
before subsequent polymerization. If persistent xylose phospho-
rylation occurs, the transference of a GlcNAc residue, catalyzed
by EXTL2, terminates HS chain elongation (24). FAM20B also
undergoes a 2.5-fold deregulation, which reinforces this proposal.
With regard to enzymes responsible for the fine structure of
CS chains, there were no significant changes in any of the 4-
O sulfotransferases or in GlcA epimerase. By contrast, CHST3,
responsible for sulfation at C-6 of GalNAc, experienced a signif-
icant deregulation. Although the other two enzymes capable of
transferring a sulfate to this position, encoded by CHST15 and
CHST7, showed no alteration in their levels in high-grade tumors,
CHST3 downregulation may have greater relevance when consid-
ering that CHST15 and CHST7 transcript levels are about two
orders of magnitude lower than CHST3, which could significantly
influence the sulfation of CS in C-6. Finally, the addition of sulfate
groups of uronic acid residues, catalyzed by chondroitin UST at
C2 increased sevenfold.
To evaluate the expression of CS chains in NETs by immuno-
histochemistry using tissue arrays, we used a monoclonal anti-CS
antibody CS-56. This antibody reacts preferentially with CS-D
(sulfated at C-2 and C-6), but is also able to recognize other types
of structures, including CS-A, -B, -C, and -E (57). Normal tissue
showed a mild staining, also present in isolated intestinal epithe-
lial cells. In contrast, well-differentiated NETs showed focal stro-
mal staining that was enhanced in poorly differentiated tumors.
However, it is necessary to consider that the differential transcrip-
tion studies were performed using tumor tissue samples with the
greatest homogeneity and cellularity possible, hence their results
essentially reflect events that take place in the tumor cells and not
in the stroma. In the same way, the existence of stromal reaction
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with abnormal expression of PGs and increased concentration of
CS in numerous tumors has been described (12, 58, 59).
Finally, a result of note common to all sections analyzed in
this work was the absence of significant correlations between the
expression of these molecules and the anatomic location of the
tumors, suggesting that the alterations described are common
features of all NETs.
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